P46937 (YAP1_HUMAN) Homo sapiens (Human)
Transcriptional coactivator YAP1 UniProtKBInterProSTRINGInteractive Modelling
504 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4; Isoform 5; Isoform 6; Isoform 7; Isoform 8; Isoform 9);
3 identical sequences: Pongo abelii: A0A2J8XX39; Pan troglodytes: K6ZN56, A0A803KKE4
It is possible new templates exist for this target since these models were created.
Available Structures
39 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Crystal structure of human YAP and TEAD complex |
Heteromer P28347; | |||||
| Assess | ||||||
| Crystal structure of Protein Scalloped in complex with YAP peptide |
Heteromer P30052; | 2×ACT; | ||||
| Assess | ||||||
| Crystal structure of TEAD4 in complex with YAP peptide |
Heteromer Q15561; | 2×MYR; | ||||
| Assess | ||||||
| Crystal structure of human TEAD1 and disulfide-engineered YAP |
Heteromer P28347; | 1×CL; | ||||
| Assess | ||||||
| YAP65 (L30K mutant) WW domain in Complex with GTPPPPYTVG peptide |
Heteromer Q96G27; | |||||
| Assess | ||||||
| TEAD4 (216-434);E263A+Y429F COMPLEXED WITH YAP PEPTIDE (60- 100);S94A AND MYRISTOATE (COVALENTLY BO… |
Heteromer Q15561; | 1×MYR; 1×PO4; | ||||
| Assess | ||||||
| X-ray structure of TEAD4(Y429H) mutant) complexed with YAP (wildtype): Molecular and structural cha… |
Heteromer Q15561; | 1×MYR; 2×PO4; | ||||
| Assess | ||||||
| TEAD4 (216-434) COMPLEXED WITH YAP PEPTIDE (60-100);S94A AND MYRISTOATE (COVALENTLY BOUND) AT 1.70A… |
Heteromer Q15561; | 1×MYR; | ||||
| Assess | ||||||
| X-ray structure of TEAD4(E263A+Y429F mutant) complexed with YAP(wildtype): The role of residual fle… |
Heteromer Q15561; | 1×MYR; 4×PO4; | ||||
| Assess | ||||||
| X-ray structure of TEAD4 (wildtype) complexed with YAP (wildtype): The role of residual flexibility… |
Heteromer Q15561; | 1×MYR; 1×GOL; | ||||
| Assess | ||||||
| TEAD4 COMPLEXED WITH YAP PEPTIDE AND MYRISTATE (COVALENTLY BOUND) |
Heteromer Q15561; | 1×GOL; 1×MYR; | ||||
| Assess | ||||||
| TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) A… |
Heteromer Q15561; | 1×MYR; | ||||
| Assess | ||||||
| TEAD4 (216-434);E263A COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 1.97… |
Heteromer Q15561; | 1×MYR; | ||||
| Assess | ||||||
| TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.05… |
Heteromer Q15561; | 1×MYR; | ||||
| Assess | ||||||
| TEAD4 (216-434) COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.1A (P412… |
Heteromer Q15561; | 1×GOL; 1×MYR; | ||||
| Assess | ||||||
| TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100); S94A AND MYRISTOATE (COVALENTLY BOUND) A… |
Heteromer Q15561; | 1×MYR; | ||||
| Assess | ||||||
| TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.28… |
Heteromer Q15561; | 1×MYR; | ||||
| Assess | ||||||
| YAP65 WW domain S24-Amino-Ethylsulfanyl-Acetic Acid mutant |
Heteromer Q96G27; | |||||
| Assess | ||||||
| YAP WW1 in complex with a Smad7 derived peptide |
Heteromer O15105; | |||||
| Assess | ||||||
| YAP WW2 in complex with a Smad7 derived peptide |
Heteromer O15105; | |||||
| Assess | ||||||
| Structure of the first WW domain of human YAP in complex with a phosphorylated human Smad1 derived … |
Heteromer Q15797; | |||||
| Assess | ||||||
| Structure of first WW domain of human YAP in complex with a human Smad1 doubly-phosphorilated deriv… |
Heteromer Q15797; | |||||
| Assess | ||||||
| X-ray structure of TEAD1(Y421H mutant) complexed with YAP(wildtype): Molecular and structural chara… |
Heteromer P28347; | 1×MYR; | ||||
| Assess | ||||||
| Structure of the second WW domain from human YAP in complex with a human Smad1 derived peptide |
Heteromer Q15797; | |||||
| Assess | ||||||
| 14-3-3 sigma in complex with YAP pS127-peptide |
Heteromer P31947; | 8×MG; 8×CL; 2×CA; 6×GOL; | ||||
| Assess | ||||||
| 14-3-3sigma covalently bound to peptide (chloroacetamide-Cys interaction) |
Heteromer P31947; | 8×MG; | ||||
| Assess | ||||||
| 14-3-3sigma in complex with a P129beta3P mutated YAP pS127 phosphopeptide |
Heteromer P31947; | 8×CL; 4×NA; | ||||
| Assess | ||||||
| 14-3-3sigma in complex with a L132beta3L mutated YAP pS127 phosphopeptide |
Heteromer P31947; | 2×CL; 2×MG; 2×NA; | ||||
| Assess | ||||||
| 14-3-3sigma in complex with a R124beta3R mutated YAP pS127 phosphopeptide |
Heteromer P31947; | 2×CL; 2×MG; 4×NA; | ||||
| Assess | ||||||
| Structure of 14-3-3 sigma delta C with electrophilic peptide 3MHR-5 |
Heteromer P31947; | 2×TJI; 2×MG; 6×CL; | ||||
| Assess | ||||||
| 14-3-3sigma in complex with a A130beta3A and Q133beta3Q mutated YAP pS127 phosphopeptide |
Heteromer P31947; | 2×CA; 4×CL; 6×NA; | ||||
| Assess | ||||||
| 14-3-3sigma in complex with a A130beta3A mutated YAP pS127 phosphopeptide |
Heteromer P31947; | 2×CL; 2×MG; 2×NA; | ||||
| Assess | ||||||
| 14-3-3sigma in complex with a S131beta3S mutated YAP pS127 phosphopeptide |
Heteromer P31947; | 4×CL; 2×MG; 2×NA; | ||||
| Assess | ||||||
| 14-3-3sigma in complex with a P129beta3P and L132beta3L mutated YAP pS127 phosphopeptide |
Heteromer P31947; | 4×CA; 2×CL; | ||||
| Assess | ||||||
| NMR structure of YAP1-2 WW2 domain with LATS1 PPxY motif complex | monomer | |||||
| Assess | ||||||
| NMR structure of YAP1-2 WW1 domain with LATS1 PPxY motif complex | monomer | |||||
| Assess | ||||||
| Crystal structure of the first WW domain of human YAP2 isoform | monomer | 1×SO4; | ||||
| Assess | ||||||
| YAP65 WW domain complexed to N-(n-octyl)-GPPPY-NH2 | monomer | 1×OCT; | ||||
| Assess | ||||||
| YAP65 WW domain complexed to Acetyl-PLPPY | monomer | |||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 3kys.1.B | monomer | 0.60 | 100.00 | |||
| Assess | ||||||
15 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 3kys.1.B | monomer | 0.59 | 100.00 | ||
| Assess | ||||||
| Isoform 2 | 6jk1.1.A | monomer | 0.50 | 78.90 | ||
| Assess | ||||||
| Isoform 3 | 6iur.1.D | monomer | 0.63 | 29.41 | ||
| Assess | ||||||
| Isoform 3 | 3kys.1.B | monomer | 0.52 | 100.00 | ||
| Assess | ||||||
| Isoform 5 | 5tuv.1.B | monomer | 0.61 | 46.43 | ||
| Assess | ||||||
| Isoform 5 | 3kys.1.B | monomer | 0.51 | 100.00 | ||
| Assess | ||||||
| Isoform 6 | 6iur.2.C | monomer | 0.60 | 28.00 | ||
| Assess | ||||||
| Isoform 6 | 3kys.1.B | monomer | 0.52 | 100.00 | ||
| Assess | ||||||
| Isoform 7 | 6iur.2.C | monomer | 0.62 | 25.93 | ||
| Assess | ||||||
| Isoform 7 | 3kys.1.B | monomer | 0.52 | 100.00 | ||
| Assess | ||||||
| Isoform 8 | 3kys.1.B | monomer | 0.59 | 100.00 | ||
| Assess | ||||||
| Isoform 8 | 6jk1.1.A | monomer | 0.50 | 78.90 | ||
| Assess | ||||||
| Isoform 8 | 6j68.2.A | monomer | 0.50 | 36.11 | ||
| Assess | ||||||
| Isoform 9 | 3kys.1.B | monomer | 0.60 | 100.00 | ||
| Assess | ||||||
| Isoform 9 | 6jk1.1.A | monomer | 0.51 | 78.90 | ||
| Assess | ||||||